Aptar Q2 Sales, EPS Beat; Pharma Strength Offsets Beauty Margin Pressure
ATR sits 33% above its 52-week low of $103.227.
Summary
AptarGroup delivered a clean Q2 beat with sales of $1.03B (consensus $1.008B) and adjusted EPS of $1.42 (consensus $1.35), driven by consumer healthcare and injectables. Pharma segment growth was partly offset by lower emergency medicine sales, while Beauty margins dipped on mix and resin costs. The company repurchased $50M in shares during the quarter and reiterated Q3 adjusted EPS guidance of $1.45-$1.53, first issued earlier today. The emergency medicine destocking headwind is expected to fade by Q4, setting up a potential second-half recovery. With shares at $137 and a $158 median target, the beat and buyback signal management confidence.
Updates
· SEC 8-K — AptarGroup announced Stephan B. Tanda will conclude his tenure as CEO, with Gael Touya assuming the role on September 1, 2026.
At the time of this announcement, ATR was trading at $137.25 on NYSE in the Life Sciences sector, with a market capitalization of approximately $8.5B. The 52-week trading range was $103.23 to $158.93. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Reuters.